ArticleCancer medicine2025
Genetic Association of Primary Lung Cancer With Urological Cancers: A Bidirectional Mendelian Randomization Study and SEER Database Validation.
Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundPrevious studies reported an association between lung cancer (LC) and partial urological cancers (UCs). However, the exact causal association between LC and UCs remains obscure.
methodsA two-sample bidirectional Mendelian randomization (MR) and the Genetic Risk Scores (GRS) method were used to assess the genetic relationships between LC and UCs. The risk of second primary cancer (SPC) was validated using the Surveillance, Epidemiology, and End Results (SEER) database.
resultsMR analysis demonstrated genetic associations between overall LC and lung adenocarcinoma (LUAD) with renal cell carcinoma (RCC) (overall LC: OR [95% CI] = 1.214 [1.003-1.469], p = 0.046; LUAD: OR [95% CI] = 1.144 [1.029-1.271], p = 0.012). The GRS method also yielded consistent results (overall LC: OR [95% CI] = 1.229 [1.067-1.414], p = 0.004; LUAD: OR [95% CI] = 1.125 [1.019-1.243], p = 0.020). Therefore, this study primarily focused on the significant associations between overall LC and LUAD with RCC. Meanwhile, the SEER database was exploited to confirm the correlation between primary LUAD (PLUAD) and secondary primary RCC (SPC-RCC). The results indicated that the risk of SPC-RCC after PLUAD was substantially higher than the US reference population.
conclusionsThe MR study identified genetic associations between LC and UCs, revealing an elevated risk of SPC-RCC after primary LC (PLC), particularly LUAD. This study lays a foundation for SPC-RCC prevention after PLC, indicating the necessity of enhanced surveillance of PLC patients in clinical practice and further research into the shared biological pathways to provide innovative therapeutic alternatives.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.